PT-141 10mg Peptide | Third-Party Tested | RemedyX Labs
Order PT-141 10mg research peptide online from RemedyX Labs. Verified batch COAs confirm purity and identity. Secure checkout, competitive pricing, and fast shipping.
PT-141 is a synthetic melanocortin receptor agonist, active at MC3R and MC4R, studied in controlled laboratory models of melanocortin receptor signaling and central nervous system research. Every batch is independently tested by a third-party laboratory to confirm identity and purity, with batch-specific Certificates of Analysis (COA) available for full transparency. For laboratory research use only. Not for human or animal use. Not intended for diagnostic, therapeutic, clinical, or commercial use.
- Price: 39.00 USD
- In stock
- Purity: 99%+
- CAS Number: 32780-32-8
- Molecular Formula: C7H15NO4
- Molecular Weight: 177.20
- Specification: 10mg/vial
- Contents: Lyophilized Powder
- Appearance: White to Off-White
- Intended Use: Research Only
- SKU: RXL-SKU-0024
Cited Research
The Neurobiology of Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder
This paper analyzes the neurobiological mechanisms associated with the use of bremelanotide in the context of hypoactive sexual desire disorder.
PubMed
PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction
This review discusses the use of the melanocortin agonist PT-141 as a therapeutic agent for sexual dysfunction.
PubMed
Melanocortin Receptors, Melanotropic Peptides and Penile Erection
This study examines the relationship between melanocortin receptors, melanotropic peptides, and the physiological mechanism of penile erection.
PMC
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®
The study evaluated the pharmacokinetics and pharmacodynamics of subcutaneously administered PT-141 in healthy men and those experiencing erectile dysfunction.
PubMed, 2004
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
Researchers conducted a double-blind study to determine the pharmacokinetic and pharmacodynamic effects of intranasal PT-141 administration in males.
PubMed, 2004
Safety Profile of Bremelanotide Across the Clinical Development Program
This program reviewed the overall safety profile of the melanocortin receptor agonist bremelanotide across its clinical development trajectory.
PubMed, 2022
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Researchers evaluated the long-term safety and efficacy of bremelanotide for treating hypoactive sexual desire disorder in an extension study.
PubMed, 2019
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
This randomized, placebo-controlled trial investigated dose-response relationships for bremelanotide in treating sexual dysfunctions among premenopausal women.
PMC, 2016
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response
Investigators examined whether co-administering low doses of intranasal PT-141 and sildenafil results in an enhanced erectile response in men.
PubMed, 2005
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide
Researchers performed prespecified and integrated subgroup analyses of the RECONNECT Phase 3 studies to examine bremelanotide outcomes based on specific participant characteristics.
PubMed, 2022
Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder
Reviews efficacy, safety and mechanism evidence for bremelanotide.
PMC, 2022
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Reports statistically significant improvements in desire and related distress compared with placebo.
PubMed, 2019
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Reports sustained outcomes during a 52-week extension, with interpretation limited by open-label design.
PMC, 2019
An effect on the subjective sexual response in premenopausal women after bremelanotide
Provides preliminary human evidence for subjective desire and arousal outcomes.
PubMed, 2006
Salvage of sildenafil failures with bremelanotide
Evaluates bremelanotide in men who had not responded to sildenafil.
PubMed, 2008